Zepbound vs Ozempic

Summary: Zepbound (tirzepatide) is FDA approved for weight loss with about 21% mean reduction in SURMOUNT-1, while Ozempic (semaglutide) is approved for type 2 diabetes and carries SELECT cardiovascular outcomes data Zepbound does not yet have.

This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before starting, changing, or stopping any medication.

The short version: Zepbound and Ozempic are not the same kind of drug, and they are not approved for the same thing. Zepbound is tirzepatide, a dual GIP and GLP-1 receptor agonist that the FDA approved in November 2023 for chronic weight management. Ozempic is semaglutide, a GLP-1 only agonist that the FDA approved in 2017 for type 2 diabetes. Comparing them is comparing an obesity drug to a diabetes drug that happens to cause weight loss as a side effect.

On the weight loss number, Zepbound wins by a wide margin. SURMOUNT-1 showed about a 20.9% mean body weight reduction at the 15 mg dose over 72 weeks ^[1]. STEP-1, the equivalent semaglutide trial, showed about a 14.9% mean reduction at 2.4 mg over 68 weeks ^[2]. On cardiovascular protection, the picture flips. Semaglutide has SELECT, a 17,604-patient outcomes trial that showed a 20% reduction in major adverse cardiac events in people with obesity and established heart disease ^[3]. Tirzepatide has no equivalent published outcomes trial yet.

That tradeoff frames the rest of the article.

Same drug class, different molecules, different jobs

Both are once-weekly subcutaneous injections in the broader GLP-1 drug family. Beyond that, the molecules diverge and the FDA labels diverge with them.

The dosing milligrams look small for Ozempic and larger for Zepbound, but the molecules are not interchangeable. Tirzepatide and semaglutide are chemically distinct peptides. One milligram of one does not equal one milligram of the other any more than a milligram of caffeine equals a milligram of nicotine. The comparison that matters is what each drug delivers at its approved maximum dose, not the number on the vial.

Indications: this is the cleanest difference

Ozempic's label covers type 2 diabetes management as add-on to diet and exercise, and cardiovascular risk reduction in T2D patients with established cardiovascular disease ^[5]. Nothing on the Ozempic label mentions weight loss as a primary indication. When a clinician prescribes Ozempic for weight loss, that prescription is off-label, and insurance plans increasingly deny it for that reason.

Zepbound's label covers chronic weight management in adults with obesity (BMI 30 or higher) or overweight (BMI 27 or higher) with at least one weight-related comorbidity such as hypertension, type 2 diabetes, dyslipidemia, or cardiovascular disease ^[4]. In 2024 the FDA added a second indication: moderate-to-severe obstructive sleep apnea in adults with obesity. A clinician prescribing Zepbound for weight loss is prescribing on-label, and that is the central reason coverage and access patterns differ from Ozempic.

For people who have both type 2 diabetes and obesity, both drugs are options. Zepbound is on-label for the obesity. Ozempic is on-label for the diabetes. Many patients in that situation end up on tirzepatide under its diabetes brand name (Mounjaro) instead, which keeps the molecule the same and shifts the insurance billing to the diabetes side.

Weight loss: the SURMOUNT-1 vs STEP-1 comparison

The two landmark trials were not head-to-head, but they were designed similarly and the populations were comparable. That makes a cautious cross-trial comparison the best available estimate until SURMOUNT-5 results are widely incorporated into prescribing.

SURMOUNT-1 enrolled adults with BMI of 30 or higher (or 27 with a comorbidity), without diabetes ^[1]. At the 5 mg, 10 mg, and 15 mg arms, mean body weight reductions were 15.0%, 19.5%, and 20.9% respectively. About 91% of participants on the 15 mg dose lost at least 5% of body weight, and 36% lost at least 25% of body weight. Those numbers are why Zepbound became the highest-efficacy weight loss drug on the US market at launch.

STEP-1 ran a similar population at the 2.4 mg semaglutide dose used in Wegovy ^[2]. Mean reduction was 14.9% versus 2.4% on placebo. About 86% of participants lost at least 5%, and 32% lost at least 15%. Ozempic itself maxes out at 2.0 mg per week for diabetes, slightly below the 2.4 mg Wegovy dose, so a strict apples-to-apples weight loss comparison between Zepbound and Ozempic at their maximum approved doses would favor Zepbound by an even larger margin than the trial cross-comparison suggests.

The one published direct head-to-head, SURPASS-2, compared tirzepatide and semaglutide in type 2 diabetes patients and showed tirzepatide outperformed semaglutide on both A1C and weight loss at every dose tested. That trial used Mounjaro and Ozempic rather than Zepbound and Wegovy, but the molecules are identical.

Cardiovascular outcomes: Ozempic has SELECT, Zepbound does not yet

SELECT is the trial that gave semaglutide its cardiovascular protection claim in non-diabetic obesity. It enrolled 17,604 adults with BMI of 27 or higher and pre-existing cardiovascular disease but no diabetes, randomized to semaglutide 2.4 mg or placebo for a mean follow-up of about 40 months ^[3]. The primary outcome, a composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke, fell by 20% in the semaglutide arm. The 95% confidence interval excluded 1.0 cleanly, and the result held across pre-specified subgroups.

SELECT studied the semaglutide molecule, not tirzepatide. The protective effect is presumed to extend to Ozempic and Wegovy at standard doses because the molecule is the same, though Ozempic's specific cardiovascular outcomes data in T2D comes from SUSTAIN-6 rather than SELECT.

Tirzepatide's cardiovascular outcomes trial is SURPASS-CVOT, which is comparing tirzepatide to dulaglutide in 13,299 adults with type 2 diabetes and atherosclerotic CVD. Results are expected in 2025 to 2026. Until those numbers land, Zepbound does not have a documented cardiovascular outcomes claim. The drug almost certainly produces some cardiovascular benefit (every other GLP-1 receptor agonist tested at that question has) but until the trial reads out, the label cannot make that claim.

For a patient with established heart disease, that distinction often tilts the conversation toward semaglutide.

Side effects: similar profile, slightly worse on Zepbound

Both drugs cause gastrointestinal side effects driven by the same mechanism: slowed gastric emptying and CNS satiety signals that change how the gut feels. Nausea, diarrhea, vomiting, constipation, and abdominal pain dominate the adverse event tables in both SURMOUNT-1 and STEP-1.

Counterintuitively, the STEP-1 numbers for GI side effects ran slightly higher than the SURMOUNT-1 numbers, even though Zepbound is the stronger weight loss drug. Both trials reported similar overall discontinuation rates from adverse events, in the 5% to 7% range. The clinical takeaway is that most patients tolerate both drugs through titration if the dose escalation is paced correctly, and the side effect profiles are more alike than different at therapeutic doses.

Serious but rare risks apply to both. Both labels carry boxed warnings for thyroid C-cell tumors based on rodent data. Both list acute pancreatitis, gallbladder disease, acute kidney injury (usually from dehydration secondary to vomiting), and severe hypersensitivity reactions. Both list a risk of hypoglycemia when combined with insulin or sulfonylureas. Neither is approved for use in pregnancy or in patients with a personal or family history of medullary thyroid carcinoma or MEN-2.

Dosing schedules

Both are once-weekly subcutaneous injections, same day each week, with or without food, at any time of day. Both come in pen devices.

Zepbound starts at 2.5 mg per week as a tolerance step, not a therapeutic dose. The label-recommended titration is 2.5 mg weekly for four weeks, then 5 mg weekly. Increase by 2.5 mg every four weeks as tolerated until reaching a maintenance dose of 5, 10, or 15 mg ^[4]. Pen strengths exist at 2.5, 5, 7.5, 10, 12.5, and 15 mg, each as a single-use auto-injector with a fixed 0.5 mL volume.

Ozempic starts at 0.25 mg per week for four weeks (also a tolerance step, not a therapeutic dose). The label-recommended titration is 0.25 mg for four weeks, then 0.5 mg for at least four weeks, then escalate to 1.0 mg or 2.0 mg if needed based on glycemic targets ^[5]. The Ozempic pen is a multi-dose device that delivers calibrated doses from a single cartridge, with separate pen formats for 0.25 to 0.5 mg, 1.0 mg, and 2.0 mg doses.

Both labels say to skip a missed dose and resume the next scheduled dose if more than five days have passed since the missed dose. If less than five days, take the missed dose as soon as remembered.

Cost and insurance

List prices are roughly similar. Zepbound's list price is about $1,060 per month for any pen strength. Ozempic's list price is about $1,000 per month. Real out-of-pocket cost depends entirely on insurance and savings programs.

Insurance coverage looks very different between the two. Ozempic is covered by most commercial insurance plans for type 2 diabetes patients. Coverage for off-label weight loss prescribing has tightened sharply since 2023, and many large plans now deny Ozempic when the diagnosis code is anything other than T2D. Zepbound coverage for weight loss varies by plan. Some commercial plans cover it. Medicare statutorily does not cover weight loss drugs, which excludes Zepbound from Part D regardless of the prescriber's documentation. The 2024 sleep apnea indication created a narrow Medicare coverage path for patients with documented OSA, which is still being implemented at the plan level.

Manufacturer savings programs help on both sides. Lilly's commercial savings card can bring Zepbound down to as little as $25 per month with commercial insurance that covers it, and $550 per month through Lilly Direct for patients paying cash for the 2.5 mg and 5 mg single-dose vials. Novo Nordisk's Ozempic savings card has similar copay-reduction terms for commercially insured patients with T2D.

Switching from Ozempic to Zepbound

Patients on Ozempic for weight loss who want the bigger weight loss number commonly ask about switching to Zepbound. The switch is medically straightforward but should always be supervised by a prescriber. A few specifics:

• Start Zepbound at the standard 2.5 mg starting dose, not at a dose intended to match the semaglutide dose you were on. The molecules are different and the titration is dose-dependent for tolerability.
• Take the first Zepbound dose seven days after the last Ozempic dose. Both are dosed weekly, so this preserves the once-weekly cadence.
• Expect the same titration timeline as a new starter: four weeks at 2.5 mg, then escalate by 2.5 mg every four weeks. The GI side effects often return briefly during the switch even if Ozempic was well tolerated, because tirzepatide engages the GIP receptor that semaglutide does not touch.
• Weight loss typically continues without a stall, and many patients report appetite suppression intensifies within two to four weeks on tirzepatide compared to where they plateaued on semaglutide.

The reverse switch (Zepbound to Ozempic) is uncommon but also straightforward. Stop Zepbound, wait seven days, start Ozempic at 0.25 mg, follow the standard titration. Expect appetite suppression to soften somewhat after the switch because semaglutide hits the satiety circuits less aggressively at its maximum dose than tirzepatide does at its maximum dose.

Zepbound vs other GLP-1 options for weight loss

Zepbound, Wegovy, and Saxenda are the three FDA-approved injectable GLP-1 medications with weight loss as the primary indication. Mounjaro and Ozempic are the same molecules as Zepbound and Wegovy respectively but labeled for diabetes. The 2025 launch of oral semaglutide for obesity (Wegovy pills, distinct from Rybelsus) added an oral option for patients who do not want to inject. On head-to-head and cross-trial weight loss numbers, the rough hierarchy is tirzepatide (Zepbound) > semaglutide (Wegovy) > liraglutide (Saxenda), with oral semaglutide landing somewhere below injected semaglutide at equivalent doses due to lower bioavailability.

Retatrutide, Lilly's triple GIP/GLP-1/glucagon agonist, has produced phase 2 weight loss numbers north of 24% but is not yet FDA approved. Survodutide and orforglipron are other late-stage candidates. None of these change the current decision today, which sits between Zepbound and Wegovy at the high efficacy end and Ozempic as the off-label diabetes-labeled option.

Who each drug fits best

Zepbound is the choice when weight loss is the primary goal, the patient meets the BMI criteria, and there is no urgent need for cardiovascular outcomes data on the prescription label. The 21% mean reduction at 15 mg is the highest of any single-agent injectable on the US market.

Ozempic is the choice when type 2 diabetes is the primary diagnosis, A1C reduction is the primary target, and the patient benefits from documented cardiovascular protection. The SELECT and SUSTAIN-6 data give Ozempic something Zepbound does not have, and for older patients with established heart disease or stroke history, that data often outweighs the difference in raw weight loss potential.

For T2D plus obesity, Mounjaro is often the better fit than Ozempic at the prescription level, since the tirzepatide molecule produces both the A1C reduction and the larger weight loss without going off-label.

FAQ

Is Zepbound the same as Ozempic?

No. Zepbound is tirzepatide and Ozempic is semaglutide. Different molecules, different receptor targets, different FDA indications. Zepbound is approved for weight loss; Ozempic is approved for type 2 diabetes.

Which causes more weight loss, Zepbound or Ozempic?

Zepbound causes more. SURMOUNT-1 showed about 20.9% mean weight loss at 15 mg over 72 weeks. STEP-1, using the same semaglutide molecule as Ozempic at the higher Wegovy dose of 2.4 mg, showed about 14.9% over 68 weeks.

What are the main side effect differences between Zepbound and Ozempic?

Both cause GI side effects (nausea, diarrhea, vomiting, constipation) at similar overall rates. In the trial data, semaglutide reported slightly higher nausea and vomiting rates at maximum dose than tirzepatide. Discontinuation rates from side effects ran around 7% in both.

Can I switch from Ozempic to Zepbound?

Yes, with prescriber supervision. Stop Ozempic, wait seven days, start Zepbound at 2.5 mg weekly and follow the standard four-week titration. Do not start at a dose intended to match your previous semaglutide dose.

Does Zepbound have cardiovascular outcomes data like Ozempic does?

Not yet. Ozempic has SELECT (20% reduction in major adverse cardiac events) and SUSTAIN-6. Tirzepatide's outcomes trial, SURPASS-CVOT, is expected to read out in 2025 to 2026.

Is Zepbound vs Wegovy the same comparison as Zepbound vs Ozempic?

No. Wegovy is semaglutide at 2.4 mg approved for weight loss. Ozempic is the same molecule at lower doses (up to 2.0 mg) approved for diabetes. Zepbound vs Wegovy is the apples-to-apples weight loss comparison.

Why do I see Zepbound vs Ozempic comparisons if they are not even for the same condition?

Because both became viral as "Ozempic" got used colloquially for any GLP-1 weight loss drug. The honest comparison for weight loss is Zepbound vs Wegovy. The comparison for diabetes management is Mounjaro vs Ozempic.

Which is cheaper, Zepbound or Ozempic?

List prices are similar (about $1,060 for Zepbound, $1,000 for Ozempic per month). With insurance, Ozempic is usually cheaper if you have type 2 diabetes. Without insurance, Lilly Direct sells Zepbound 2.5 mg and 5 mg single-dose vials at $349 to $550 per month.

Will insurance cover Ozempic for weight loss?

Increasingly, no. Major commercial plans have tightened coverage and many now deny Ozempic prescriptions with non-diabetes diagnosis codes. Zepbound is the on-label option for weight loss coverage when a plan covers obesity medications.

Can I take Zepbound if I have type 2 diabetes?

Yes, though Mounjaro (same molecule, T2D label) is usually the better-billed option. Zepbound carries hypoglycemia risk warnings when combined with insulin or sulfonylureas, same as Ozempic.

What this article does not cover

This page is the brand-to-brand comparison of Zepbound and Ozempic. Adjacent topics covered in their own pages on this site include Zepbound vs Wegovy (the apples-to-apples weight loss comparison), Mounjaro vs Ozempic (the T2D comparison between the same molecules), tirzepatide vs semaglutide at the molecule level, and the cost and insurance landscape for GLP-1 medications. Use the sidebar or search to find them.